赖氨肌醇维B_(12)联合莫沙必利治疗儿童功能性消化不良的临床观察

目的:观察赖氨肌醇维B12联合莫沙必利治疗儿童功能性消化不良的临床疗效和安全性。方法:464例功能性消化不良患儿按随机数字表法均分为对照组和观察组。两组患儿均指导改善生活方式,调整饮食结构和习惯,去除与症状相关的可能发病因素等常规治疗。对照组患儿给予枸橼酸莫沙必利片0.2 mg/kg,口服,tid;观察组患儿在对照组治疗的基础上给予赖氨肌醇维B12口服液5 ml/次,口服,tid。两组患儿疗程均为2周。观察两组患儿的临床疗效,治疗前、后症状评分及不良反应发生情况。结果:治疗后观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前两组患儿各症状评分比较,差异无统计学意义(P>0.05);治疗后两组患儿各症状评分均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患儿治疗期间均未见严重不良反应发生。结论:赖氨肌醇维B12联合莫沙必利治疗儿童功能性消化不良疗效显著,安全性较好。

Clinical Observation of Lysine Inosite and Vitamin B12 Combined with Mosapride for Functional Dyspepsia in Children

OBJECTIVE： To observe therapeutic efficacy of lysine inosite and vitamin B12 combined with mosapride for functional dyspepsia （FD） in children. METHODS： A total of 464 patients with FD were randomly divided into control group and ob servation group. Both group were given routine treatment, such as improving mode of life, adjusting diet structure and habits, resolving relevant factors of disease. Control group was given Mosapride citrate tablets 0.2 mg/kg, 3 times a day; observation group was given Lysine inosite and vitamin B12 oral solution 5 ml/time orally, 3 times a day. Treatment course of 2 groups lasted for 2 weeks. Clinical efficacies of 2 groups were observed, and symptom score and the occurrence of ADR were compared between 2 groups before and after treatment. RESULTS： Total effective rate of observation group was significantly higher than that of control group; there was statistical significance （P〈0.05）. The scores of the symptoms had no statistical significance between 2 groups before treatment （P〉0.05） ; those of 2 groups after treatment were significantly lower than before, those of observation group were lower than those of control group; there was statistical significance （P〈0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： The lysine inosite and vitamin B12 combined with mosapride could improve FD in children with sound safety.